We have two types of hair, says dermatologist Elizabeth Houshmand. Vellus hairs, or “peach fuzz,” cover virtually our entire ...

Vertex Pharmaceuticals Inc.’s new non-opioid painkiller is being placed on a tier that means it might be costlier than other pain treatments on UnitedHealth Group Inc.’s approved drug lists.

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...

To recreate her warm caramel honey brown hair color, he says to ask for “a warm, rich honey brown with golden caramel highlights throughout. The highlights should be concentrated around the face ...

Promise. I don’t know about you, but the moment the sun comes out and the weather warms up, I feel an irresistible urge to chop off my dry, winter-worn hair, commit to a fresh new cut ...

When it comes to achieving soft, healthy locks, everyone knows that a consistent hair care routine is key. Sure, you may already have a go-to clarifying shampoo, moisturizing conditioner ...

Mar. 18, 2025 — Small amounts of a common antibiotic and anti-inflammatory drug can curb symptoms where a misplaced immune reaction (e.g., autoimmunity) can cause permanent hair loss ...

The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $503.20, representing a -1.37% change from its previous close. Amicus Therapeutics (FOLD) reported earnings 30 days ago.

Having one of the best hair dryers is a must if you want you want to get your locks from wet to dry and styled in minimal time and with minimal effort. We've tested out a wide range of blow dryers ...

Starting Monday, Claude 3.7 Sonnet will be available in the Claude app through Anthropic’s API, Amazon Bedrock and Google Cloud’s Vertex AI at a rate of $3 per million input tokens and $15 per ...

Top seeds have been decided for all 10 classes in Section V boys basketball. East High seeks seventh straight finals trip. Junior Zion Parson is one of the remaining members from East High's last ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...